Advertisement

Diffuse Liver Disease: Cirrhosis and Vascular Diseases

  • Tobias J. Heye
  • Elmar M. Merkle

Abstract

A variety of diseases may lead to liver cirrhosis, with alcohol abuse, viral hepatitis, and steatohepatitis being the most common entities in the Western world. Liver cirrhosis is one of the main risk factors for developing hepatocellular carcinoma (HCC). The radiologist’s role in the workup of patients with liver cirrhosis is of utmost importance, as imaging findings oftentimes serve as the basis for selecting the most appropriate treatment strategy, e.g., surgical resection, locoregional therapy, or transplantation.

Keywords

Inferior Vena Cava Primary Biliary Cirrhosis Primary Sclerosing Cholangitis Hereditary Hemorrhagic Telangiectasia Unenhanced Compute Tomography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195:13–28.PubMedCrossRefGoogle Scholar
  2. 2.
    Cruite I, Schroeder M, Merkle EM, Sirlin CB (2010) Gadoxetate-enhanced MR imaging of the liver: Part 2: Protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 195:29–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Husarik DB, Gupta RT, Ringe KI et al (2011) Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents. Acad Radiol 18:1549–1554.PubMedCrossRefGoogle Scholar
  4. 4.
    Anon (1995) Terminology of nodular hepatocellular lesions. Hepatology 22:983–993.CrossRefGoogle Scholar
  5. 5.
    Chou CT, Chen YL, Su WW et al (2010) Characterization of cirrhotic nodules with gadoxetic acid-enhanced magnetic resonance imaging: the efficacy of hepatocyte-phase imaging. J Magn Reson Imaging 32: 895–902.PubMedCrossRefGoogle Scholar
  6. 6.
    Rhee H, Kim MJ, Park MS, Kim KA (2012) Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRI. Br J Radiol 85: e837–e844.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Bartolozzi C, Battaglia V, Bargellini I et al (2013) Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 38:290–296.PubMedCrossRefGoogle Scholar
  8. 8.
    Zech CJ, Reiser MF, Herrmann KA (2009) Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 27:114–124.PubMedCrossRefGoogle Scholar
  9. 9.
    Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245–1255.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  • Tobias J. Heye
    • 1
  • Elmar M. Merkle
    • 1
  1. 1.Department of RadiologyUniversity Hospital BaselBaselSwitzerland

Personalised recommendations